Secondary lymphoblastic leukemia has been rarely reported in patients with multiple myeloma.
Case Reports
We report 3 cases of secondary lymphoblastic leukemia in multiple myeloma patients. They shared a similar phenotype of myeloma cells and secondary lymphoblasts. The chemotherapy treatments in the 3 patients were complex due to various factors.
Conclusions
Multiple immune defects caused by exposure to a variety of agents can play an important role in the development of secondary lymphoblastic leukemia. Microscopic morphology and flow cytometry are important means to detect secondary malignancies in multiple myeloma. Further clinical, experimental and genetic studies of secondary malignancies in multiple myeloma will be necessary in the future.
JunxunLJuanLXiuzhenTJuanOBohuangZJunruLComparing five diagnostic criteria for multiple myeloma: a retrospective study of 227 cases. Tumori. 2014; 100 (2): 207–213.
2.
GarciaMKCohenLGuoYElectroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014; 7 (1): 41.
3.
MailankodySPfeifferRMKristinssonSYRisk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood. 2011; 118 (15): 4086–4092.
4.
PanBLentzschSThe application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther. 2012; 136 (1): 56–68.
5.
OrmerodAFauselCAAbonourRKielPJObservations of second primary malignancy in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012; 12 (2): 113–117.
6.
SrivastavaGRanaVLacyMQLong-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia. 2013; 27 (10): 2062–2066.
7.
LauLGTanLKKoayESLiuTCAcute lymphoblastic leukemia after tandem autologous stem cell transplantations for multiple myeloma. Leukemia. 2005; 19 (2): 299–301.
8.
UedaKYamamotoGShinoharaAHangaishiAKurokawaMEarly onset of acute lymphoblastic leukemia with MLL rearrangement after autologous stem cell transplantation for multiple myeloma. Ann Hematol. 2009; 88 (8): 813–814.
9.
PiszczJBolkunLCichockaEKloczkoJSecondary acute lymphoblastic leukaemia in a multiple myeloma patient. Contemp Oncol (Pozn). 2012; 16 (6): 593–595.
10.
Chanan-KhanASonneveldPSchusterMWAnalysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008; 26 (29): 4784–4790.
11.
San MiguelJFSchlagRKhuagevaNKPersistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013; 31 (4): 448–455.
12.
HaslettPACorralLGAlbertMKaplanGThalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998; 187 (11): 1885–1892.
13.
VerbonAJuffermansNPSpeelmanPA single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob Agents Chemother. 2000; 44 (9): 2286–2290.
14.
UsmaniSZSextonRHoeringASecond malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood. 2012; 120 (8): 1597–1600.
15.
StewartAKTrudelSBahlisNJA randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood. 2013; 121 (9): 1517–1523.
16.
SchüttPBrandhorstDStellbergWImmune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma. 2006; 47 (8): 1570–1582.
17.
DasanuCAImmune alterations in untreated and treated multiple myeloma. J Oncol Pharm Pract. 2012; 18 (2): 257–263.
18.
BergsagelDEBaileyAJLangleyGRThe chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med. 1979; 301 (14): 743–748.
19.
CuzickJErskineSEdelmanDGaltonDAA comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. Br J Cancer. 1987; 55 (5): 523–529.
20.
Secker-WalkerLMMoormanAVBainBJMehtaABSecondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23Workshop. Leukemia. 1998; 12 (5): 840–844.
21.
SandovalCPuiCHBowmanLCSecondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol. 1993; 11 (6): 1039–1045.
22.
LahjoujiABachirFBennaniSThe immunophenotype of adult T acute lymphoblastic leukemia in Morocco. Exp Oncol. 2015; 37 (1): 64–69.
23.
LiuBLiRWuHJChenYClinical study on prognosis of acute leukemia subtypes Ly + AML and My + ALL. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007; 15 (2): 421–424.
24.
JiangNGChenXMZhuHLImmunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010; 18 (6): 1405–1409.
25.
LahjoujiABachirFBennaniSClinical importance of myeloid antigen expression in Moroccan patients with adult B-lineage acute lymphoblastic leukemia. Neoplasma. 2013; 60 (5): 553–560.
